- Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
- Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
- Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
- Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
- Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
- Elevai Labs Inc. Reports First Quarter 2024 Financial Results
- Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
- Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
- Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.437 |
---|---|
High | 0.4726 |
Low | 0.4331 |
Bid | 0.451 |
Offer | 0.4585 |
Previous close | 0.433 |
Average volume | 96.50k |
---|---|
Shares outstanding | 18.89m |
Free float | 3.72m |
P/E (TTM) | -- |
Market cap | 8.18m USD |
EPS (TTM) | -0.2665 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 18:16 BST.
More ▼